Late-breaking data: New treatment option for women with recurrent ovarian
(Embargoed until Monday, 15 September 2008, 16:30 CEST)
Combining the new drug trabectedin with pegylated liposomal doxorubicin
provides clinical benefit to women with relapsed ovarian cancer, according
to new results. The combination, which importantly does not include a
platinum drug, challenges the current standard of treatment for women whose
cancer recurs at least 6 months after first-line treatment, said Associate
Professor Bradley J. Monk from the University of California Irvine Medical
Adding iron to darbepoetin therapy helps with chemotherapy-induced
(Embargoed until Monday, 15 September 2008, 08:45 CEST)
For patients suffering from chemotherapy-induced anaemia, adding intravenous iron to treatments with the drug darbepoietin alfa results in better haematologic response, and a faster improvement in the condition, US researcher Michael Auerbach reports.
An estimated 25 million people alive today have survived cancer, a number that is likely to grow substantially in the future thanks in part to improved treatments such as personalised therapies, leading experts will tell patients at the 7th ESMO Patient Seminar. Providing appropriate care to these survivors, many of whom face lingering medical complications and psychological repercussions, will pose a difficult challenge for healthcare systems around the world.
Further late-breaking data available close to the Congress...
|SOURCE ESMO European Society for Medical Oncology|
Copyright©2008 PR Newswire.
All rights reserved